Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy》.pdf

Leukemia Research 39 (2015) 938–944 Contents lists available at ScienceDirect Leukemia Research j o u r na l h o m e p a g e : w w w. elsev /locate/leu kres Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy Yinjun Lou, Yafang Ma, Shanshan Suo, Wanmao Ni, Yungui Wang, Hanzhang Pan, Hongyan Tong, Wenbin Qian, Haitao Meng, Wenyuan Mai, Jian Huang, Wenjuan Yu, Juyin Wei, Liping Mao, Jie Jin ∗ Department of Hematology, Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, China a r t i c l e i n f o a b s t r a c t Article history: Prognostic factors for patients with acute promyelocytic leukemia (APL) treated in the context of arsenic Received 20 February 2015 trioxide (ATO)-based frontline regimes have not been established clearly. We retrospectively analyzed Received in revised form 15 May 2015 the clinical features, immunophenotypes, Fms-like tyrosine kinase-3 internal tandem duplication (FLT3- Accepted 16 May 2015 ITD), and outcomes of 184 consecutive newly diagnosed APL patients treated by intravenous ATO-based Available online 2 July 2015 therapy. The median age was 40 years (14–77 years). The early death rate was 4.9% (9/184 patients). With a median follow-up time of 36 months (9–74 months), the 3-year relapse-free survival (RFS) and overall Keywords: survival